surmount-1 tirzepatide non-diabetic obesity trial Weight reduction with different doses of Tirzepatide in Surmount 1

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh

26.90

★★★★☆4.8 (126)

For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The

22.43

★★★★★4.9 (98)

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

27.83

★★★★★5.0 (157)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity

29.23

★★★★★4.7 (84)

Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials

23.25

★★★★★4.9 (203)

Clinical trials of subcutaneous tirzepatide (SURMOUNT-1, -2 and -3

25.95

★★★★★5.0 (176)

💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers

20.70

★★★★★4.8 (132)